TGFβ pathway inhibition in the treatment of non-small cell lung cancer

PÖ Eser, PA Jänne - Pharmacology & therapeutics, 2018 - Elsevier
Advanced non-small cell lung cancer (NSCLC) continues to be an incurable family of
thoracic malignancies that is chronically managed with chemotherapy, targeted therapy, and …
被引用次数：99 相关文章

[引用][C] TGFβ pathway inhibition in the treatment of non-small cell lung cancer

PÖ Eser, PA Jänne - Pharmacology & Therapeutics, 2018 - cir.nii.ac.jp
TGFβ pathway inhibition in the treatment of non-small cell lung cancer | CiNii Research CiNii
国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …

TGFβ pathway inhibition in the treatment of non-small cell lung cancer.

PÖ Eser, PA Jänne - Pharmacology & Therapeutics, 2017 - europepmc.org
Advanced non-small cell lung cancer (NSCLC) continues to be an incurable family of
thoracic malignancies that is chronically managed with chemotherapy, targeted therapy, and …

TGFβ pathway inhibition in the treatment of non-small cell lung cancer

PÖ Eser, PA Jänne - Pharmacology & therapeutics, 2018 - pubmed.ncbi.nlm.nih.gov
Advanced non-small cell lung cancer (NSCLC) continues to be an incurable family of
thoracic malignancies that is chronically managed with chemotherapy, targeted therapy, and …